← Human Trials & Peer-Reviewed Studies
The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study
Plain-language guide to PMID 16400650 (2006): randomized controlled trial study of Vitamin D, K2, Magnesium and Zinc in 32 patients.
Key Facts
- PMID
- 16400650
- Journal
- Cancer
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Mizuta T et al. (7 authors)
- DOI
- 10.1002/cncr.21667
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Vitamin D, K2, Magnesium and Zinc.
The high recurrence rate of hepatocellular carcinoma (HCC) determines the long-term prognosis for patients with HCC.
In the current study, the authors tested the effects of menatetrenone, a vitamin K2 analog, on recurrent HCC and survival after curative treatment.
Who Took Part
The study group was 32 patients.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Sixty-one patients who were diagnosed as free of HCC after surgical resection or percutaneous local ablation were assigned randomly assigned to either a menatetrenone group (n = 32 patients) or a control group (n = 29 patients).
Disease recurrence and survival rates were analyzed in patients with HCC.
How the Study Was Run
The researchers set it up as a randomized study.
The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
What Was Measured
In the current study, the authors tested the effects of menatetrenone, a vitamin K2 analog, on recurrent HCC and survival after curative treatment.
PubMed files the paper under topics including Carcinoma, Hepatocellular, Hemostatics, Liver Neoplasms, Neoplasm Recurrence, Local, Survival Analysis and Vitamin K 2.
What This Means in Plain Language
The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 32 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2006 (Cancer), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.